期刊文献+

动脉粥样硬化性肾动脉狭窄支架术后病人的健康教育及管理 被引量:2

Health education and management of postoperative patients with atherosclerotic renal artery stenosis underwent stent implantation
下载PDF
导出
摘要 [目的]增加动脉粥样硬化性肾动脉狭窄(ARAS)病人介入治疗后随访及治疗的依从性,以减少术后并发症的发生。[方法]将行选择性及非选择性肾动脉造影并进行介入治疗的76例确诊为ARAS病人为研究对象,对病人进行健康教育,使其充分了解ARAS的危害、相关危险因素及介入治疗的并发症;进行术后随访统计术前后相关危险因素控制率。[结果]术后随访到69例病人,随访率90.79%,随访时间4个月~32个月(15.84个月±9.04个月)。病人血压、血总胆固醇、血尿酸、血清同型半胱氨酸的控制率术前分别为46.4%、66.7%、68.1%、41.3%,术后随访分别提高至65.2%、89.9%、84.1%、81.0%;介入后再狭窄6例(8.7%)。[结论]对ARAS病人进行健康教育,可提高病人对相关危险因素的控制率,减少术后并发症的发生。
出处 《护理研究(上旬版)》 2006年第8期2021-2023,共3页 Chinese Nursing Researsh
基金 卫生部临床学科重点项目基金资助(20010913)
  • 相关文献

参考文献10

  • 1王梅,王海燕.慢性缺血性肾脏疾病的诊断与治疗(三) 动脉粥样硬化引起的肾动脉狭窄的诊断与治疗[J].中华内科杂志,2002,41(1):56-58. 被引量:22
  • 2Leertouwer TC,Gussenhoven EJ, Bosch JL, et al. Stent lancement for renal arterial stenosis:Where do we stand? A Meta-analysis[ J ]. Radiology, 2000,216: 78 - 85.
  • 3Safian RD, Textor SC. Medical progress: Renal - artery stenosis[J].N Engl J Med, 2001,344 : 431 - 442.
  • 4Arend WP, Michel BA, Bloch DA, et al. The American College of Rheurnatology 1990 criteria for the classification of Takayasu arteritis[J] .Arthritis Rheum,1990,33:l129- 1134.
  • 5Anonymus K. Clinical practice guidelines on hypertension and antihypertensive agents in chronic kindney disease[J]. Am J Kidney Dis,2004,43 : S65 - S73.
  • 6Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular diseasecausing end stage renal disease, incidence, clinical correlates, and outcomes:A 202 year clinical experience[J]. Am J Kidney Dis, 1994,24:622- 629.
  • 7O'Neil EA, Hansen KJ, Canzenello VJ, et al. Prevalence of ischemicnephropathy in patients with renal insufficiency [ J ]. Am Surg, 1992,58 : 485 - 490.
  • 8'基层医生高血压检出、评估、治疗及预防综合规范研究'课题组.北京市城乡社区卫生服务中心高血压防治现状的对比研究[J].中华心血管病杂志,2004,32(11):1021-1025. 被引量:52
  • 9全国高胆固醇血症控制状况多中心研究协作组.高胆固醇血症临床控制状况多中心协作研究——达标率及影响因素[J].中华心血管病杂志,2002,30(2):109-114. 被引量:176
  • 10Howie JGR, Heancy DJ, Maxwell M, et al. Quality of general practice consulations: Cross sectional survey [ J ]. BMJ, 1999,319 : 738 -743.

二级参考文献25

  • 1Slamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol a nd risk of premature death from coronary heart disease continuous and graded ? F indings in 356,222 primary screenees of the Multiple Risk Factor Intervention Tr ial (MRFIT). JAMA, 1986,256:2823-2828.
  • 2Castelli WP, Garrison RJ,Wilson PwF, et al. Incidence of coronary heart disea se and lipoprotein cholesterol levels: the Framing ham Study. JAMA, 1986, 256:28 35-2838.
  • 3Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S).Lancet,1994,344:1383 -1389.
  • 4Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary- prevention t ri al with gemfibrozil in middle-aged men with dislipidemia. Safety of treatment ,c hages in risk factors, and incidence of coronary heart disease. N Engl J Med, 1 987,317:1237-1245.
  • 5Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease wit h pravastatin in men with hypercholesterolemia. West of Scotland Coronary Preven tion Study Group. N Engl J Med,1995,333:1301-1307.
  • 6Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary e v ents with lovastatin in men and women with average cholesterol levels: results o f AFCAPS/TexCAPS. Air Force/Texas Coronary Artherosclerosis Prevention Study. JAMA .1998;279:1615-1622.
  • 7Summary of the second report of the National Cholesterol Education Program (NC EP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholestero l in Adults ( Adult Treatment Panel II Report). JAMA, 1993, 269:3015-3023.
  • 8Report of the National Cholesterol Education Program Expert Panel on Detection , Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Pan el. Arch Intern Med, 1998, 148:36-69.
  • 90 Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L -TAP):a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein choles terol goals. Arch Intern Med, 2000, 160:459-467.
  • 10Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal Ddsease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis, 1994, 24: 622-629.

共引文献247

同被引文献13

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部